Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where U. E. K. Wolf-Schnurrbusch is active.

Publication


Featured researches published by U. E. K. Wolf-Schnurrbusch.


Diabetes Care | 2010

Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study) A 12-month, randomized, controlled, double-masked, multicenter phase II study

Pascale Massin; Francesco Bandello; Justus G. Garweg; Lutz L. Hansen; Simon P. Harding; Michael Larsen; Paul Mitchell; Dianne Sharp; U. E. K. Wolf-Schnurrbusch; Margarita Gekkieva; Andreas Weichselberger; Sebastian Wolf

OBJECTIVE The expression of vascular endothelial growth factor (VEGF) is elevated in diabetic macular edema (DME). Ranibizumab binds to and inhibits multiple VEGF variants. We investigated the safety and efficacy of ranibizumab in DME involving the foveal center. RESEARCH DESIGN AND METHODS This was a 12-month, multicenter, sham-controlled, double-masked study with eyes (age >18 years, type 1 or 2 diabetes, central retinal thickness [CRT] ≥300 μm, and best corrected visual acuity [BCVA] of 73–39 ETDRS letters [Early Treatment Diabetic Retinopathy Study]) randomly assigned to intravitreal ranibizumab (0.3 or 0.5 mg; n = 51 each) or sham (n = 49). The treatment schedule comprised three monthly injections, after which treatment could be stopped/reinitiated with an opportunity for rescue laser photocoagulation (protocol-defined criteria). After month 1, dose-doubling was permitted (protocol-defined criteria, injection volume increased from 0.05 to 0.1 ml and remained at 0.1 ml thereafter). Efficacy (BCVA and CRT) and safety were compared between pooled ranibizumab and sham arms using the full analysis set (n = 151, patients receiving ≥1 injection). RESULTS At month 12, mean ± SD BCVA improved from baseline by 10.3 ± 9.1 letters with ranibizumab and declined by 1.4 ± 14.2 letters with sham (P < 0.0001). Mean CRT reduction was 194.2 ± 135.1 μm with ranibizumab and 48.4 ± 153.4 μm with sham (P < 0.0001). Gain of ≥10 letters BCVA from baseline occurred in 60.8% of ranibizumab and 18.4% of sham eyes (P < 0.0001). Safety data were consistent with previous studies of intravitreal ranibizumab. CONCLUSIONS Ranibizumab is effective in improving BCVA and is well tolerated in DME. Future clinical trials are required to confirm its long-term efficacy and safety.


Investigative Ophthalmology & Visual Science | 2009

Macular Thickness Measurements in Healthy Eyes Using Six Different Optical Coherence Tomography Instruments

U. E. K. Wolf-Schnurrbusch; Lala Ceklic; C. K. Brinkmann; Milko E Iliev; Manuel Frey; S. P. Rothenbuehler; Volker Enzmann; Sebastian Wolf

PURPOSE To compare central retinal thickness (CRT) measurements in healthy eyes by different commercially available OCT instruments and to compare the intersession reproducibility of such measurements. METHODS Six different OCT instruments (Stratus OCT [Carl Zeiss Meditec, Inc. Dublin, CA], SOCT Copernicus [Reichert/Optopol Technology, Inc., Depew, NY], Spectral OCT/SLO [Opko/OTI, Inc., Miami, FL], RTVue-100 [Optovue Corp., Fremont, CA], Spectralis HRA+OCT [Heidelberg Engineering, Inc., Heidelberg, Germany], and Cirrus HD-OCT [Carl Zeiss Meditec, Inc.]) were used to assess CRT in both eyes of healthy subjects. Measurements were performed in two different sessions on the same day with each of the systems. From these measurements, the mean CRT was calculated. For the assessment of the intersession reproducibility of the instruments, we calculated the coefficient of the variation of test-retest variation. RESULTS Twenty healthy subjects were included in the study. Compared with the Stratus OCT all spectral OCT instruments showed significantly higher CRTs. The Spectralis HRA+OCT and Cirrus HD-OCT showed similar CRT values but significantly higher values than did all other instruments. The coefficients of variation for repeated measurements was 3.33% for the Stratus OCT, 0.46% for the Spectralis HRA+OCT, 3.09% for the Cirrus HD-OCT, 2.23% for the OCT/SLO, 2.77% for the RTVue-100 OCT, and for the SOCT 3.5%, respectively. discussion. The six OCT systems provided different results for CRT. The measurements with the Stratus OCT showed the lowest thicknesses, whereas those with the Cirrus HD-OCT and Spectralis HRA+OCT yielded the highest ones. These discrepancies can be explained by the differences in the retinal segmentation algorithms used by the various OCT systems. Whereas the Spectralis HRA+OCT and Cirrus HD-OCT include the RPE layer in the retinal segmentation, the other instruments do not. The data imply that the different OCT systems cannot be used interchangeably for the measurement of macular thickness.


Investigative Ophthalmology & Visual Science | 2009

Safety and Efficacy of Ranibizumab Treatment in Patients With Diabetic Macular Edema: 12-Months Results of the Resolve Study

Sebastian Wolf; Pascale Massin; Francesco Bandello; D. Sharp; Paolo Lanzetta; Michael Larsen; U. E. K. Wolf-Schnurrbusch; Margarita Gekkieva


Investigative Ophthalmology & Visual Science | 2009

Spatial Distribution of Macular Pigment and Its Relation to the Fovea Size

U. E. K. Wolf-Schnurrbusch; Sebastian Wolf; D. Völker; C. K. Brinkmann; S. P. Rothenbuehler; François C. Delori


Investigative Ophthalmology & Visual Science | 2010

Detection of Chlamydia Pneumoniae and Factors of the Complement System in Neovascular Membranes of Patients With Age-Related Macular Degeneration

Volker Enzmann; Roberto Hess; F. Jordi; Sebastian Wolf; U. E. K. Wolf-Schnurrbusch


Investigative Ophthalmology & Visual Science | 2009

Enhancement of Macular Pigment by Oral Lutein Supplementation Study (EMPOLS): First Results

C. K. Brinkmann; S. P. Rothenbuehler; U. E. K. Wolf-Schnurrbusch; Sebastian Wolf


Investigative Ophthalmology & Visual Science | 2017

Distribution and progression patterns of retinal low-reflective intraretinal spaces in Type 2 Idiopathic Macular Telangiectasia.

Ferenc B. Sallo; Irene Leung; U. E. K. Wolf-Schnurrbusch; Bingqian Liu; Kiyoko Gocho; Valérie Krivosic; Tunde Peto; Daniel Pauleikhoff; Traci E. Clemons; Michel Paques; Emily Y. Chew; A. Gaudric; Alan C. Bird


Diabetes Care | 2011

Bezpieczeństwo i skuteczność ranibizumabu w leczeniu cukrzycowego obrzęku plamki żółtej (badanie RESOLVE*) Trwające 12 miesięcy randomizowane, wieloośrodkowe badanie kliniczne II fazy z grupą kontrolną i podwójnie ślepą próbą

P Massini; Francesco Bandello; Jg Garweg; Ll Hansen; Simon P. Harding; Michael Larsen; Paul Mitchell; Dianne Sharp; U. E. K. Wolf-Schnurrbusch; Margarita Gekkieva; Andreas Weichselberger; Sebastian Wolf


Investigative Ophthalmology & Visual Science | 2010

Macular Pigment Density at the Site of Altered Fundus Autofluorescence

S. P. Rothenbuehler; U. E. K. Wolf-Schnurrbusch; Sebastian Wolf


Investigative Ophthalmology & Visual Science | 2010

Results of Treatment of Exudative ARMD With Ranibizumab in a Clincal Setting

Sebastian Wolf; R. Ruehl; Carsten Framme; U. E. K. Wolf-Schnurrbusch

Collaboration


Dive into the U. E. K. Wolf-Schnurrbusch's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Francesco Bandello

Vita-Salute San Raffaele University

View shared research outputs
Top Co-Authors

Avatar

Tunde Peto

Queen's University Belfast

View shared research outputs
Top Co-Authors

Avatar

Michael Larsen

University of Copenhagen

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge